Cargando…
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling
KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major con...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373085/ https://www.ncbi.nlm.nih.gov/pubmed/34151545 http://dx.doi.org/10.1002/advs.202100250 |
_version_ | 1783739882763452416 |
---|---|
author | Zhang, Baoyuan Zhang, Yan Zhang, Jiangwei Liu, Ping Jiao, Bo Wang, Zaiqi Ren, Ruibao |
author_facet | Zhang, Baoyuan Zhang, Yan Zhang, Jiangwei Liu, Ping Jiao, Bo Wang, Zaiqi Ren, Ruibao |
author_sort | Zhang, Baoyuan |
collection | PubMed |
description | KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major concern. Here, it is demonstrated that KRAS G12C inhibition induces sustained activation of focal adhesive kinase (FAK) and show that a combination therapy comprising KRAS G12C inhibition and a FAK inhibitor (IN10018) achieves synergistic anticancer effects. It can simultaneously reduce the extent of drug resistance. Diverse CDX and PDX models of KRAS G12C mutant cancer are examined and synergistic benefits from the combination therapy are consistently observed. Mechanistically, it is found that both aberrant FAK–YAP signaling and FAK‐related fibrogenesis impact on the development of KRAS G12C inhibitor resistance. This study thus illustrates the mechanism of resistance of cancer to the treatment of KRAS G12C inhibitor, as well as an innovative combination therapy to improve treatment outcomes for KRAS G12C mutant cancers. |
format | Online Article Text |
id | pubmed-8373085 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83730852021-08-24 Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling Zhang, Baoyuan Zhang, Yan Zhang, Jiangwei Liu, Ping Jiao, Bo Wang, Zaiqi Ren, Ruibao Adv Sci (Weinh) Research Articles KRAS mutation is one of the most prevalent genetic drivers of cancer development, yet KRAS mutations are until very recently considered undruggable. There are ongoing trials of drugs that target the KRAS G12C mutation, yet acquired drug resistance from the extended use has already become a major concern. Here, it is demonstrated that KRAS G12C inhibition induces sustained activation of focal adhesive kinase (FAK) and show that a combination therapy comprising KRAS G12C inhibition and a FAK inhibitor (IN10018) achieves synergistic anticancer effects. It can simultaneously reduce the extent of drug resistance. Diverse CDX and PDX models of KRAS G12C mutant cancer are examined and synergistic benefits from the combination therapy are consistently observed. Mechanistically, it is found that both aberrant FAK–YAP signaling and FAK‐related fibrogenesis impact on the development of KRAS G12C inhibitor resistance. This study thus illustrates the mechanism of resistance of cancer to the treatment of KRAS G12C inhibitor, as well as an innovative combination therapy to improve treatment outcomes for KRAS G12C mutant cancers. John Wiley and Sons Inc. 2021-06-20 /pmc/articles/PMC8373085/ /pubmed/34151545 http://dx.doi.org/10.1002/advs.202100250 Text en © 2021 The Authors. Advanced Science published by Wiley‐VCH GmbH https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Zhang, Baoyuan Zhang, Yan Zhang, Jiangwei Liu, Ping Jiao, Bo Wang, Zaiqi Ren, Ruibao Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title | Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title_full | Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title_fullStr | Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title_full_unstemmed | Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title_short | Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK–YAP Signaling |
title_sort | focal adhesion kinase (fak) inhibition synergizes with kras g12c inhibitors in treating cancer through the regulation of the fak–yap signaling |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373085/ https://www.ncbi.nlm.nih.gov/pubmed/34151545 http://dx.doi.org/10.1002/advs.202100250 |
work_keys_str_mv | AT zhangbaoyuan focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT zhangyan focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT zhangjiangwei focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT liuping focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT jiaobo focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT wangzaiqi focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling AT renruibao focaladhesionkinasefakinhibitionsynergizeswithkrasg12cinhibitorsintreatingcancerthroughtheregulationofthefakyapsignaling |